Lansoprazole vs Rabeprazole
## Overview
Lansoprazole and rabeprazole are both effective PPIs. Rabeprazole's key advantage is its non-enzymatic primary metabolism pathway, providing more consistent efficacy across CYP2C19 genotypes. Lansoprazole offers the unique ODT (SoluTab) formulation.
## Mechanism of Action
Both irreversibly inhibit parietal cell H+/K+-ATPase. Rabeprazole activates more rapidly at physiologic parietal cell canalicular pH, potentially explaining a faster onset of acid suppression.
## Pharmacokinetics
Lansoprazole: CYP2C19 + CYP3A4, subject to pharmacogenomic variability. Rabeprazole: primarily non-enzymatic hydrolysis, less CYP2C19-dependent.
## Clinical Evidence
Both equivalent for GERD, PUD, H. pylori eradication (as PPI component of triple/quadruple therapy). Rabeprazole-containing H. pylori regimens may show higher eradication rates in CYP2C19 ultra-rapid metabolizers.
## Key Takeaways
- Rabeprazole: CYP2C19-independent, consistent across genotypes
- Lansoprazole: SoluTab ODT unique; CYP2C19-dependent
- H. pylori eradication: rabeprazole may be preferred in CYP2C19 UM populations
Kesimpulan
Rabeprazole is preferred in CYP2C19 ultra-rapid metabolizers and for H. pylori eradication regimens where consistent acid suppression across genotypes is important. Lansoprazole is preferred when ODT formulation is needed.